2 Feb 2022 , 12:21 PM
Windlas Biotech has concluded SAHPRA (South African Health Products Regulatory Authority) inspection audit report for the Plant-IV situated at Dehradun with zero critical observations/ deficiencies, zero major deficiencies and some minor deficiencies.
Hitesh Windlass, Managing Director — Windlas Biotech said, “We are very happy to receive zero critical observations and deficiencies. The successful completion of the audit will enable us to open up new geography and strengthen our presence in South Africa.”
The company had undergone the inspection audit from 20th to 29th September 2021.
Furthermore, the company is set to announce its financial performance for the quarter ending December 2021 (Q3FY22) later today.
At around 12.17 pm, Windlas Biotech was trading at Rs274.15 per piece up by 4.9% on Sensex. The stock was near the day's high of Rs279 per piece.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
